Renovia Inc, set to move forward with several pelvic floor disorder products after its founding CEO sourced $42 million in Series B round and venture debt. He managed to raise $32 million in Series B and $10 million in venture debt. Renovia Inc., is a pharmaceutical startup that is focused on finding treatment for pelvic floor disorders in women.
Renovia is developing diagnostic and therapeutic products that will put pelvic floor cases to rest. According to a research, over 250 million women across the world have urinary incontinence, one type of pelvic floor disorders. One of the first products Renovia developed, Leva, was approved in April by FDA.
The Series B round of financing was conducted by Perceptive Advisors and Ascension Ventures which are based in New York and Missouri respectively. The funds will be used to develop four more therapeutic and diagnostic products including a modern generation of the Leva device.
Marc Beer expressed his excitement for the support he garnered from leading investors in the healthcare sector. In a statement, he stated that the supportive investors share the same vision with his company to improve the lives of women suffering from pelvic floor disorders around the world. He looks to avail valuable data to their customers that will inform new treatment options, drive greater knowledge and ultimately, improve understanding of the disorders. In the long-run, long-term healthcare costs will be reduced.
Marc Beer has led a successful career in the healthcare industry working in prominent companies and establishing companies. He served at OvaScience as a strategic consultant. OvaScience had shown interests of merging with Millendo Therapeutics. Learn more: https://gazetteday.com/2018/10/marc-beer-funding-renovia/
A Look at the Career Life of Marc Beer
Marc Beer is the co-founder and CEO of the Boston-based medtech company. He brings over 25 years of development and commercialization experience in the pharmaceutical, biotechnology, diagnostic and device industries. He earned his BS degree from Miami University, OHIO. He has worked at several companies and founded a couple of companies that thrived in the industry.
As the Founding CEO of ViaCell, he led the biotechnology company from inception to when it had over 300 employees and went public. The company was later acquired by PerkinElmer in 2007. At the same time, Beer was a member of Erytech Pharma’s Board of Directors. Mr. Beer was the Founding Chairman of the board of directors as well as chairman of the compensation committee of Good Start Genetics. He serves in various capacities at Minerva Neurosciences. He sits in the Miami University Business Advisory Council as a member. Formerly, he sat in the Notre Dame Research and Commercialization Advisory Committee as well as Norte Dame Graduate Studies Research and Advisory Council as a member. The work background of Marc Beer is extensive. His dedicated service in the industry has promoted the industry significantly.